Enzyme replacement therapy in α-mannosidosis guinea-pigs

Molecular Genetics and Metabolism

Volumn 89, Issue 1-2, 2006, Pages 48-57

  Crawley, Allison C ^a   King, Barbara ^a   Berg, Thomas ^a   Meikle, Peter J ^a   Hopwood, John J ^a  

^a Lysosomal Diseases Research Unit   (Australia)

Author keywords

Mannosidase; Animal model; Enzyme replacement; Genetic disease; Guinea pig; Lysosomal storage disease; Therapy

Indexed keywords

ALPHA MANNOSIDASE; MANNOSE; OLIGOSACCHARIDE; RECOMBINANT ENZYME; RECOMBINANT HUMAN LYSOSOMAL ALPHA MANNOSIDASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CELL VACUOLE; CENTRAL NERVOUS SYSTEM DISEASE; CIRCULATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE MODEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; ENZYME ACTIVITY; ENZYME REPLACEMENT; GANGLION; GENETIC DISORDER; GUINEA PIG; HISTOCHEMISTRY; HUMORAL IMMUNITY; KIDNEY; LIVER; LONG TERM CARE; LYSOSOME; LYSOSOME STORAGE DISEASE; MANNOSIDOSIS; MASS SPECTROMETRY; NEUROPATHOLOGY; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; SPLEEN; STATISTICAL SIGNIFICANCE; TRIGEMINUS GANGLION; URINE LEVEL;

ALPHA-MANNOSIDASE; ALPHA-MANNOSIDOSIS; ANIMALS; ANTIBODIES; BRAIN; DISEASE MODELS, ANIMAL; GUINEA PIGS; HUMANS; INJECTIONS, INTRAVENOUS; ISLETS OF LANGERHANS; KIDNEY; LIVER; MASS SPECTROMETRY; RECOMBINANT PROTEINS; SPLEEN;

CAVIA; CAVIA PORCELLUS;

EID: 33747008880     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2006.05.005     Document Type: Article

References (47)

1. Thomas G.H. Disorders of glycoprotein degradation: α-mannosidosis, β-mannosidosis, fucosidosis and sialidosis. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease. eighth ed. (2001), McGraw-Hill, New York 3507-3533
2. Crawley A.C., Jones M.Z., Bonning L.E., Finnie J.W., and Hopwood J.J. α-Mannosidosis in the guinea-pig: a new animal model for lysosomal storage disorders. Pediatr. Res. 46 (1999) 501-509
3. Berg T., and Hopwood J.J. Alpha-mannosidosis in the guinea-pig: cloning of the lysosomal alpha-mannosidase cDNA and identification of a missense mutation causing alpha-mannosidosis. Biochim. Biophys. Acta 1586 (2002) 169-176
4. Walkley S.U., Thrall M.A., Dobrenis K., Huang M., March P.A., Siegel D.A., and Wurzelmann S. Bone marrow transplantation corrects the enzyme defect in neurons of the central nervous system in a lysosomal storage disease. Proc. Natl. Acad. Sci. USA 91 (1994) 2970-2974
5. Wall D.A., Grange D.K., Goulding P., Daines M., Luisiri A., and Kotagel S. Bone marrow transplantation for the treatment of alpha-mannosidosis. J. Pediatr. 133 (1998) 282-285
6. Grewal S.S., Shapiro E.G., Krivit W., Charnas L., Lockman L.A., Delaney K.A., Davies S.M., Wenger D.A., Rimell F.L., Abel S., Grovas A.C., Orchard P.J., Wagner J.E., and Peters C. Effective treatment of alpha-mannosidosis by allogeneic hematopoietic stem cell transplantation. J. Pediatr. 144 (2004) 569-573
7. Vite C.H., McGowan J.C., Niogi S.N., Passini M.A., Drobatz K.J., Haskins M.E., and Wolfe J.H. Effective gene therapy for an inherited CNS disease in a large animal model. Ann. Neurol. 57 (2005) 355-364
8. Weinreb N.J., Charrow J., Andersson H.C., Kaplan P., Kolodny E.H., Mistry P., Pastores G., Rosenbloom B.E., Scott C.R., Wappner R.S., and Zimran A. Effectiveness of enzyme replacement therapy in 1028 patients with type I Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher registry. Am. J. Med. 113 (2002) 112-119
9. Andersson H.C., Charrow J., Kaplan P., Mistry P., Pastores G.M., Prakesh-Cheng A., Rosenbloom B.E., Scott C.R., Wappner R.S., and Weinreb N.J. International Collaborative Gaucher Group U.S. Regional Coordinators, Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet. Med. 7 (2005) 105-110
10. Kakkis E.D., Muenzer J., Tiller G.E., Waber L., Belmont J., Passage M., Izykowski B., Phillips J., Doroshow R., Walot I., Hoft R., and Neufeld E.F. Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 344 (2001) 182-188
11. Wraith E.J., Hopwood J.J., Fuller M., Meikle P.J., and Brooks D.A. Laronidase treatment of mucopolysaccharidosis I. BioDrugs. 19 (2005) 1-7
12. Harmatz P., Whitley C.B., Waber L., Pais R., Steiner R., Plecko B., Kaplan P., Simon J., Butensky E., and Hopwood J.J. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J. Pediatr. 144 (2004) 574-580
13. Amalfitano A., Bengur A.R., Morse R.P., Majure J.M., Case L.E., Veerling D.L., Mackey J., Kishnani P., Smith W., McVie-Wylie A., Sullivan J.A., Hoganson G.E., Phillips III J.A., Schaefer G.B., Charrow J., Ware R.E., Bossen E.H., and Chen Y.T. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet. Med. 3 (2001) 132-138
14. Van den Hout J.M., Kamphoven J.H., Winkel L.P., Arts W.F., De Klerk J.B., Loonen M.C., Vulto A.G., Cromme-Dijkhuis A., Weisglas-Kuperus N., Hop W., Van Hirtum H., Van Diggelen O.P., Boer M., Kroos M.A., Van Doorn P.A., Van der Voort E., Sibbles B., Van Corven E.J., Brakenhoff J.P., Van Hove J., Smeitink J.A., de Jong G., Reuser A.J., and Van der Ploeg A.T. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113 (2004) e448-e557
15. Eng C.M., Banikazemi M., Gordon R.E., Goldman M., Phelps R., Kim L., Gass A., Winston J., Dikman S., Fallon J.T., Brodie S., Stacy C.B., Mehta D., Parsons R., Norton K., O'Callaghan M., and Desnick R.J. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet. 68 (2001) 711-722
16. Clarke J.T., and Iwanochko R.M. Enzyme replacement therapy of Fabry disease. Mol. Neurobiol. 32 (2005) 43-50
17. Muenzer J. The mucopolysaccharidoses: A heterogeneous group of disorders with variable pediatric presentations. J. Pediatr. 144 (2004) 527-534
18. Sands M.S., Vogler C., Kyle J.W., Grubb J.H., Levy B., Galvin N., Sly W.S., and Birkenmeier E.H. Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J. Clin. Invest. 93 (1994) 2324-2331
19. Vogler C., Levy B., Galvin N.J., Thorpe C., Sands M.S., Barker J.E., Baty J., Birkenmeier E.H., and Sly W.S. Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy. Pediatr. Res. 45 (1999) 838-844
20. Gliddon B., and Hopwood J.J. Enzyme-replacement therapy from birth delays the development of behaviour and learning problems in mucopolysaccharidosis type IIIA mice. Pediatr. Res. 56 (2004) 65-72
21. Urayama A., Grubb J.H., Sly W.S., and Banks W.A. Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier. Proc. Natl. Acad. Sci. USA. 101 (2004) 12658-12663
22. Dunder U., Kaartinen V., Valtonen P., Vaananen E., Kosma V.M., Heisterkamp N., Groffen J., and Mononen I. Enzyme replacement therapy in a mouse model of aspartylglycosaminuria. FASEB J. 14 (2000) 361-367
23. Roces D.P., Lullmann-Rauch R., Peng J., Balducci C., Andersson C., Tollersrud O., Fogh J., Orlacchio A., Beccari T., Saftig P., and Von Figura K. Efficacy of enzyme replacement therapy in α-mannosidosis mice: a preclinical animal study. Hum. Mol. Genet. 15 (2004) 1979-1988
24. Matzner U., Herbst E., Hedayati K.K., Lullmann-Rauch R., Wessig C., Schroder S., Eistrup C., Moller C., Fogh J., and Gieselmann V. Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy. Hum. Mol. Genet. 14 (2005) 1139-1152
25. Vogler C., Levy B., Grubb J.H., Galvin N., Tan Y., Kakkis E., Pavloff N., and Sly W.S. From The Cover: Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc. Natl. Acad. Sci. USA 102 (2005) 14777-14782
26. Berg T., King B., Meikle P.J., Nilssen O., Tollersrud O.K., and Hopwood J.J. Purification and characterization of recombinant human lysosomal alpha-mannosidase. Mol. Genet. Metab. 73 (2001) 18-29
27. Triguero D., Buciak J., and Pardridge W. Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J. Neurochem. 54 (1990) 1882-1888
28. Baggot J.D. Disposition and fate of drugs in the body. In: Booth N.H., and McDonald L.E. (Eds). Veterinary pharmacology and therapeutics. fifth ed. (1982), The Iowa State University Press, Ames 36-69
29. Yu W.H., Zhao K.W., Ryazantsev S., Rozengurt N., and Neufeld E.F. Short-term enzyme replacement in the murine model of Sanfilippo syndrome type B. Mol. Genet. Metab. 71 (2000) 573-580
30. Jones M.Z., Brumfield L.K., King B.M., Hopwood J.J., and Byers S. Recombinant caprine H-3-[N-acetylglucosamine-6-sulfatase] and human H-3-[N-acetylgalactosamine-4-sulfatase]-plasma clearance, tissue distribution, and cellular uptake in the rat. J. Mol. Neurosci. 11 (1998) 223-232
31. Crawley A.C., Brooks D.A., Muller V.J., Petersen B.A., Isaac E.L., Bielicki J., King B.M., Boulter C.D., Moore A.J., Fazzalari N.L., Anson D.S., Byers S., and Hopwood J.J. Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome. J. Clin. Invest. 97 (1996) 1864-1873
32. Shull R.M., Kakkis E.D., McEntee M.F., Kania S.A., Jonas A.J., and Neufeld E.F. Enzyme replacement in a canine model of Hurler syndrome. Proc. Natl. Acad. Sci. USA 91 (1994) 12937-12941
33. Nilssen O., Berg T., Riise H.M., Ramachandran U., Evjen G., Hansen G.M., Malm D., Tranebjaerg L., and Tollersrud O.K. Alpha-Mannosidosis: functional cloning of the lysosomal alpha-mannosidase cDNA and identification of a mutation in two affected siblings. Hum. Mol. Genet. 6 (1997) 717-726
34. Koster A., von Figura K., and Pohlmann R. Mistargeting of lysosomal enzymes in Mr 46000 mannose 6-phosphate receptor-deficient mice is compensated by carbohydrate-specific endocytic receptors. Eur. J. Biochem. 224 (1994) 685-689
35. Banks W.A. 2004, Blood-brain barrier transport of cytokines: a mechanism for neuropathology. Curr. Pharm. Des. 11 (2005) 973-984
36. Hirakawa H., Okajima S., Nagaoka T., Kubo T., Takamatsu T., and Oyamada M. Regional differences in blood-nerve barrier function and tight-junction protein expression within the rat dorsal root-ganglion. Neuroreport 15 (2004) 405-408
37. Passini M.A., Lee E.B., Heuer G.G., and Wolfe J.H. Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream. J. Neurosci. 22 (2002) 6437-6446
38. Hennig A.K., Levy B., Mosinger Ogilvie J., Vogler C.A., Galvin N., Bassnett S., and Sands M.S. Intravitreal gene therapy reduces lysosomal storage in specific areas of the CNS in mucopolysaccharidosis VII mice. J. Neurosci. 23 (2003) 3302-3307
39. Crawley A.C., Ramsay S.L., Byers S., Hopwood J.J., and Meikle P.J. Monitoring Dose Response of Enzyme Replacement Therapy in Feline Mucopolysaccharidosis Type VI by Tandem Mass Spectrometry. Pediatr. Res. 55 (2004) 585-591
40. Ramsay S.L., Meikle P.J., and Hopwood J.J. Determination of monosaccharides and disaccharides in mucopolysaccharidoses patients by electrospray ionisation mass spectrometry. Mol. Genet. Metab. 78 (2003) 193-204
41. Ramsay S.L., Meikle P.J., Hopwood J.J., and Clements P.R. Profiling oligosaccharidurias by electrospray tandem mass spectrometry: Quantifying reducing oligosaccharides. Anal. Biochem. 345 (2005) 30-46
42. Rozaklis T., Ramsay S.L., Whitfield P.D., Ranieri E., Hopwood J.J., and Meikle P.J. Determination of oligosaccharides in Pompe disease by electrospray ionization tandem mass spectrometry. Clin. Chem. 48 (2002) 131-139
43. Fuller M., Meikle P.J., and Hopwood J.J. Glycosaminoglycan degradation fragments in mucopolysaccharidosis I. Glycobiology 14 (2004) 443-450
44. Kakkis E.D., McEntee M.F., Schmidtchen A., Neufeld E.F., Ward D.A., Gompf R.E., Kania S., Bedolla C., Chien S.L., and Shull R.M. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem. Mol. Med. 58 (1996) 156-167
45. Kakkis E.D., Schuchman E., He X., Wan Q., Kania S., Wiemelt S., Hasson C.W., O'Malley T., Weil M.A., Aguirre G.A., Brown D.E., and Haskins M.E. Enzyme replacement therapy in feline mucopolysaccharidosis I. Mol. Genet. Metab. 72 (2001) 199-208
46. Tomatsu S., Orii K.O., Vogler C., Grubb J.H., Snella E.M., Gutierrez M., Dieter T., Holden C.C., Sukegawa K., Orii T., Kondo N., and Sly W.S. Production of MPS VII mouse (Gus(tm(hE540A × mE536A)Sly)) doubly tolerant to human and mouse beta-glucuronidase. Hum. Mol. Genet. 12 (2003) 961-973
47. Auclair D., Hopwood J.J., Brooks D.A., Lemontt J.F., and Crawley A.C. Replacement therapy in Mucopolysaccharidosis type VI: advantages of early onset of therapy. Mol. Genet. Metab. 78 (2003) 163-174